超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

Presidio Pharmaceuticals  
Presidio是一家位于舊金山的制藥公司，其專業領域是發現和開發泛基因型HCV口服治療藥物。目前，公司正致力于開發針對HCV NS5A 和NS5B基因的新型抑制劑。 PPI-668是在研的、泛基因型、每日給藥一次的NS5A抑制劑。在健康志愿者以及HCV感染者中開展的早期臨床研究結果顯示，到目前為止，觀察到PPI-668具有良好的耐受性，未發生嚴重或重度不良事件，而且未觀察到明顯的與治療有關的臨床副反應或實驗室檢查異常。 PPI-668所達到的血藥濃度足以抑制大多數之前存在耐藥變異的病毒，而且單劑給藥就可達到穩態水平。在一項針對PPI-668單藥治療應用于 GT1 HCV感染者的臨床試驗中，在治療1至2天后的病毒載量降幅達到了3.5—3.7 log10 HCV。該藥應用于GT3 HCV感染者的有效性也已被證實。

Presidio公司的NS5B抑制劑PPI-383是一種新型、泛基因型、非核苷類抑制劑，該藥具有抑制所有主要的HCV基因型的潛力。這一化合物目前正處于針對健康受試者的I期臨床試驗中。

Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio’s current focus is on effective therapies for hepatitis C virus (HCV) infection. With a current pipeline consisting of compounds targeting both the NS5A and NS5B proteins of HCV, Presidio is well positioned to compete in the growing HCV therapy market (see Programs & Pipeline for more details). Presidio’s goal is to discover and advance small-molecule, antiviral drug candidates that are potent, have pan-genotypic antiviral activity, offer convenient once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance. The best future combination regimens will require such characteristics, to simplify patient treatment and to ensure that drug therapy will be effective against the wide variety of known HCV genotypes.